Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma.

The Journal of clinical endocrinology and metabolism - 1 Apr 2018

Giordano Thomas J, Haugen Bryan R, Sherman Steven I, Shah Manisha H, Caoili Elaine M, Koenig Ronald J

Abstract excerpt

Context: A subset of thyroid carcinomas expresses an oncogenic paired box 8 (PAX8) and peroxisome proliferator activated receptor γ (PPARγ) fusion protein (PPFP). The PPARγ/PPFP ligand pioglitazone is highly therapeutic in a transgenic mouse model of PPFP thyroid carcinoma, but whether pioglitazone is therapeutic in patients with PPFP thyroid carcinoma is unknown. Case Description: Tumor blocks from 40 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoma, Oxyphilic
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Pioglitazone

Share to Soft Tissue Neoplasms

Share to Thiazolidinediones

Share to Thyroid Neoplasms

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 29373711
DOI: 10.1210/jc.2017-02533
PMCID: PMC6456920

Genes

PAX8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma.PMID 29373711Read ↗

The PAX8 / PPARγ Fusion Oncogene as a Potential Therapeutic Target in Follicular Thyroid CarcinomaSemantic proximity Read ↗

The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.Semantic proximity Read ↗

Detection of PAX8-PPARG fusion transcripts in archival thyroid carcinoma samples by conventional RT-PCR.Semantic proximity Read ↗

The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibitionSemantic proximity Read ↗

Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.Semantic proximity Read ↗

Association between Pax8-PPARandgamma;1 Rearrangement and Follicular Thyroid Cancer: a Meta-Analysis.Semantic proximity Read ↗

PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.Semantic proximity Read ↗

Evaluation of the PAX8/PPARG Translocation in Follicular Thyroid Cancer with a 4-Color Reverse-Transcription PCR Assay and Automated High-Resolution Fragment AnalysisSemantic proximity Read ↗

Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis.Semantic proximity Read ↗

<i>RAS</i>Point Mutations and PAX8-PPARγ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular CarcinomaSemantic proximity Read ↗

Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth.Semantic proximity Read ↗

Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.